Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Thromb Haemost 2009; 101(04): 782-785
DOI: 10.1160/TH08-09-0617
DOI: 10.1160/TH08-09-0617
Letters to the Editor
The contribution of anti-Xa and anti-IIa activities to the profibrinolytic activity of low-molecular-weight heparins
Financial support: This work was supported in part by a grant from the University of Bari.Further Information
Publication History
Received:
24 September 2008
Accepted after major revision:
16 January 2009
Publication Date:
23 November 2017 (online)
-
References
- 1 Alban S. From heparins to factor Xa inhibitors and beyond. Eur J Clin Invest 2005; 35 (01) 12-20.
- 2 Bajzar L. Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway. Arterioscler Thromb Vasc Biol 2000; 20: 2511-2518.
- 3 Gerotziafas GT, Petropoulou AD, Verdy E. et al. Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation. J Thromb Haemost 2007; 5: 955-962.
- 4 Lisman T, Adelmeijer J, Nieuwenhuis HK. et al. Enhancement of fibrinolytic potential in vitro by anticoagulant drugs targeting activated factor X, but not by those inhibiting thrombin or tissue factor. Blood Coagul Fibrinolysis 2003; 14: 557-562.
- 5 Colucci M, Binetti BM, Tripodi A. et al. Hyperprothrombinemia associated with prothrombin G20210A mutation inhibits plasma fibrinolysis through a TAFI-mediated mechanism. Blood 2004; 103: 2157-2161.
- 6 Semeraro F, Piro D, Rossiello MR. et al. Profibrinolytic activity of the direct thrombin inhibitor melagatran and unfractionated heparin in platelet-poor and platelet-rich clots. Thromb Haemost 2007; 98: 1208-1214.
- 7 Al Dieri R, Wagenvoord R, van Dedem GW. et al. The inhibition of blood coagulation by heparins of different molecular weight is caused by a common functional motif – the C-domain. J Thromb Haemost 2003; 1: 907-914.
- 8 Ghosh S, Ezban M, Persson E. et al. Activity and regulation of factor VIIa analogs with increased potency at the endothelial cell surface. J Thromb Haemost 2007; 5: 336-346.
- 9 Nagashima H. Studies on the different modes of action of the anticoagulant protease inhibitors DX-9065a and Argatroban. II. Effects on fibrinolysis. J Biol Chem 2002; 277: 50445-50449.
- 10 Weitz JI. Emerging anticoagulants for the treatment of venous thromboembolism. Thromb Haemost 2006; 96: 274-284.
- 11 Schutgens RE, Esseboom EU, Snijder RJ. et al. Low molecular weight heparin (dalteparin) is equally effective as unfractionated heparin in reducing coagulation activity and perfusion abnormalities during the early treatment of pulmonary embolism. J Lab Clin Med 2004; 144: 100-107.